Karyopharm to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Karyopharm Therapeutics (NASDAQ: KPTI), a leader in novel cancer therapies, announced its participation in two upcoming investor conferences in November 2022. The Jefferies 2022 London Healthcare Conference is scheduled for November 15, 2022, at 3:35 a.m. ET, featuring a fireside chat. The Piper Sandler 34th Annual Healthcare Conference will take place on November 29, 2022, at 11:30 a.m. ET, with a podium presentation. Webcasts of both events will be accessible for 90 days post-event on the company's investor webpage.

NEWTON, Mass., Nov. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:

Jefferies 2022 London Healthcare Conference
Format: Fireside chat
Date: Tuesday, November 15, 2022
Time: 3:35 a.m. ET / 8:35 a.m. GMT

Piper Sandler 34th Annual Healthcare Conference
Format: Podium presentation
Date: Tuesday, November 29, 2022
Time: 11:30 a.m. ET

A live webcast of the presentation and fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following each event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301670748.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What investor conferences is Karyopharm participating in November 2022?

Karyopharm Therapeutics will participate in the Jefferies 2022 London Healthcare Conference on November 15 and the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.

What is the schedule for Karyopharm's upcoming investor conferences?

The Jefferies conference is on November 15 at 3:35 a.m. ET, and the Piper Sandler conference is on November 29 at 11:30 a.m. ET.

Where can I watch Karyopharm's investor conference presentations?

Webcasts of the presentations will be available on Karyopharm's investor webpage for 90 days after each event.

What is Karyopharm Therapeutics known for?

Karyopharm is known for pioneering novel cancer therapies and developing the first-in-class oral XPO1 inhibitor, XPOVIO®.

What time are Karyopharm's events scheduled in GMT?

The Jefferies conference is at 8:35 a.m. GMT on November 15, and the Piper Sandler conference is at 4:30 p.m. GMT on November 29, 2022.